Charles River Laboratories International, Inc. (Form: 8-K)  






Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):   October 24, 2007

Charles River Laboratories International, Inc.
(Exact name of registrant as specified in its charter)

Delaware 001-15943 06-1397316
(State or other jurisdiction
(I.R.S. Employer
of incorporation) File Number) Identification No.)
251 Ballardvale St., Wilmington, Massachusetts   01887
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code:   978-658-6000

Not Applicable
Former name or former address, if changed since last report


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Top of the Form

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On October 24, 2007, the Board of Directors of Charles River Laboratories International, Inc. (the "Registrant") increased the size of the Board from seven to nine. Following the increase in the size of the Board, the Board filled a vacancy and appointed Dr. Nancy T. Chang to the Board, effective immediately. In addition, Dr. Chang has been appointed to the Compensation Committee of the Board of Directors.

There are no arrangements or understandings between Dr. Chang and any other person pursuant to which she was selected as a director, and there are no transactions in which Dr. Chang has an interest requiring disclosure under Item 404(a) of Regulation S-K. As an element of the compensation that the Registrant provides to all new non-employee directors, Dr. Chang will be receiving non-qualified options to purchase 8,500 shares of the Registrant's common stock, as well as an award of 3,000 shares of restricted stock.

Dr. Chang was the co-founder, Chief Executive Officer and Chairman of the Board at Tanox, Inc., until its recent sale to Genetech, Inc.

Top of the Form


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    Charles River Laboratories International, Inc.
October 24, 2007   By:   Joanne P. Acford
        Name: Joanne P. Acford
        Title: Corporate Senior Vice President, General Counsel and Corporate Secretary